SMARCB1 and chordoma: In line with these preclinical results, Gounder et al. reported a prolonged (>2 years) and exceptional abscopal response to radiotherapy in a patient with a SMARCB1-negative poorly differentiated chordoma who previously progressed on the EZH2 inhibitor tazemetostat [43].